Baolingbao Biology Co Ltd - Asset Resilience Ratio
Baolingbao Biology Co Ltd (002286) has an Asset Resilience Ratio of -0.77% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Baolingbao Biology Co Ltd (002286) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2023)
This chart shows how Baolingbao Biology Co Ltd's Asset Resilience Ratio has changed over time. See 002286 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Baolingbao Biology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002286 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-20.42 Million | -0.77% |
| Total Liquid Assets | CN¥-20.42 Million | -0.77% |
Asset Resilience Insights
- Limited Liquidity: Baolingbao Biology Co Ltd maintains only -0.77% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Baolingbao Biology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Baolingbao Biology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Baolingbao Biology Co Ltd (2013–2023)
The table below shows the annual Asset Resilience Ratio data for Baolingbao Biology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.77% | CN¥-20.42 Million ≈ $-2.99 Million |
CN¥2.66 Billion ≈ $389.08 Million |
-4.29pp |
| 2021-12-31 | 3.52% | CN¥106.67 Million ≈ $15.61 Million |
CN¥3.03 Billion ≈ $443.24 Million |
+3.73pp |
| 2020-12-31 | -0.21% | CN¥-5.48 Million ≈ $-802.34K |
CN¥2.62 Billion ≈ $382.76 Million |
+0.09pp |
| 2019-12-31 | -0.30% | CN¥-7.62 Million ≈ $-1.12 Million |
CN¥2.52 Billion ≈ $368.57 Million |
+0.10pp |
| 2018-12-31 | -0.41% | CN¥-10.51 Million ≈ $-1.54 Million |
CN¥2.58 Billion ≈ $377.43 Million |
-0.29pp |
| 2017-12-31 | -0.12% | CN¥-2.44 Million ≈ $-357.60K |
CN¥2.11 Billion ≈ $308.31 Million |
0.00pp |
| 2016-12-31 | -0.11% | CN¥-2.15 Million ≈ $-314.40K |
CN¥1.93 Billion ≈ $282.65 Million |
-0.02pp |
| 2015-12-31 | -0.09% | CN¥-1.81 Million ≈ $-265.48K |
CN¥1.91 Billion ≈ $280.01 Million |
+0.01pp |
| 2014-12-31 | -0.11% | CN¥-1.91 Million ≈ $-279.19K |
CN¥1.77 Billion ≈ $258.44 Million |
+0.01pp |
| 2013-12-31 | -0.12% | CN¥-2.00 Million ≈ $-292.89K |
CN¥1.68 Billion ≈ $245.28 Million |
-- |
About Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd. researches and develops, manufactures, and sells a range of functional sugars in China. The company offers prebiotics, such as isomaltooligosaccharides, galactooligosaccharides, fructooligosaccharides, bagasse trisaccharides, and xylooligosaccharides; sugar alcohols and new sugar source products, including erythritol, trehalose, crystalline fructose, alodonose, and mal… Read more